Key Points
Enasidenib inhibits mIDH2, leading to leukemic cell differentiation with emergence of functional mIDH2 neutrophils in rrAML patients. RAS pathway mutations and increased mutational burden overall are associated with a decreased response rate to mIDH2 inhibition.